Molbio Diagnostics Reports Rs 58.75 Crore Profit in Q2 Amid Mixed Market Response
Molbio Diagnostics reported a consolidated net profit of Rs 58.75 crore for the quarter ended June 2026, reversing a net loss of Rs 23.71 crore in the same period last year. Sales surged over 300% to Rs 408.38 crore from Rs 99.71 crore year-on-year. Despite these financial gains, Molbio Diagnostics' share price fell 2% on September 7 amid broader market fluctuations. Other companies like Jayaswal Neco Industries and Morepen Laboratories saw share price gains following corporate updates and capacity expansions.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (54/100). Lens Score 32/100.
Outlets measured: moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 7 Sept, 03:37 am. Other outlets followed.